Evaluation of new therapies for inflammatory bowel disease

被引：26

作者：

Carty, E ^{[1
]}

Rampton, DS ^{[1
]}

机构：

[1] Barts & London Queen Marys Sch Med & Dent, Acad Dept Adult & Paediat Gastroenterol, London E1 2AD, England

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2003年 / 56卷 / 04期

关键词：

Crohn's disease; inflammatory bowel disease; pharmacology clinical trials; treatment; ulcerative colitis;

D O I：

10.1046/j.1365-2125.2003.01965.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pathophysiology of inflammatory bowel disease (IBD) is gradually being unravelled and new therapies are being developed to target the disturbed biological processes. This article outlines the clinical features of IBD, its current therapy and pathogenesis. The difficulties for clinical pharmacologists and gastroenterologists associated with designing, executing and interpreting clinical trials in IBD are then discussed. The final section reviews methods that can used to demonstrate the pharmacological actions of new treatments in patients with IBD. It is emphasized that proof of the therapeutic efficacy of a novel agent with a specific mechanism of action yields not only clinical benefit to patients with IBD, but also indicates the importance of the targeted biochemical pathway in the pathogenesis of the disease.

引用

页码：351 / 361

页数：11

共 114 条

[1] Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease [J].